Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NBI-1070770

Other · developed by NEUROCRINE BIOSCIENCES

Phase 2 Most advanced trial (none active)

NBIX Developer

1 Registered trials

What is NBI-1070770?

NBI-1070770 is an investigational drug studied in Major Depressive Disorder.

At a glance

Drug type: Other
Therapy area: Psychiatry
Developer: NEUROCRINE BIOSCIENCES (NBIX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06267846	Phase 2	Major Depressive Disorder	Completed	NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Major Depressive Disorder

More from NEUROCRINE BIOSCIENCES

Crinecerfont FDA approved Valbenazine FDA approved Chronocort Phase 3 DITEST Phase 1 Luvadaxistat Phase 2 NBI-1065845 Phase 3 NBI-1065890 Phase 2 NBI-1117567 Phase 2 NBI-1117568 Phase 3 NBI-1117570 Phase 2 NBI-827104 Phase 2 NBI-921352 Phase 2

Sources

ClinicalTrials.gov NCT06267846

Updated Oct 3, 2026. Something wrong or missing? Report it on the NBIX page.

Follow NBIX, the company behind NBI-1070770

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z